Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman
-
- Nakao Sanshiro
- Department of Hematology, Toho University Sakura Medical Center, Japan
-
- Tanaka Sho
- Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan
-
- Abe Kazuki
- Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan
-
- Komiyama Tomomi
- Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan
-
- Sugiura Yoshiya
- Department of Surgical Pathology, Toho University Sakura Medical Center, Japan
-
- Nakaseko Chiaki
- Department of Hematology, International University of Health and Welfare School of Medicine, Japan
-
- Shimizu Naomi
- Department of Hematology, Toho University Sakura Medical Center, Japan
抄録
<p>In recent years, lesbian, gay, bisexual, and transgender (LGBT) populations have been gaining acceptance in society. However, very few cases of malignancy in the LGBT population have been reported thus far. We herein report a transgender woman receiving estrogen supplementation who developed primary mediastinal large B-cell lymphoma (PMBCL) and was treated with dose-adjusted EPOCH-rituximab (DA-EPOCH-R) therapy. The patient achieved complete remission after the sixth course of DA-EPOCH-R therapy. To help this LGBT patient continue receiving chemotherapy smoothly on admission, adjusting the hospital environment, such as the allocation of rooms, was essential. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine advpub (0), 2024
一般社団法人 日本内科学会